Biomarkers For Multiple System Atrophy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Multiple System Atrophy (MSA) is a rapidly progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. MSA is classified as an α-synucleinopathy, with glial cytoplasmic inclusions (GCIs) being the pathological hallmark. Reliable biomarkers are crucial for accurate diagnosis, distinguishing MSA from Parkinson's Disease and other synucleinopathies, and monitoring disease progression.
MSA biomarkers can be categorized based on the pathological process they reflect:
The distinction between MSA-P (parkinsonian type) and MSA-C (cerebellar type) and differentiation from PD remains clinically important.
Total α-Synuclein:
α-Synuclein Seeding Assays (RT-QuIC, PMCA):
Phosphorylated α-Synuclein (pS129):
Neurofilament Light Chain (NfL):
Neurofilament Heavy Chain (pNfH):
YKL-40:
sTREM2:
GFAP:
Blood NfL is the most validated blood biomarker for MSA:
pS129 α-Synuclein:
α-Synuclein seeding assays:
Cell-free DNA:
Orthostatic hypotension testing:
Heart rate variability:
Norepinephrine levels:
Urinary biomarkers:
Characteristic findings support MSA diagnosis:
MSA-P:
MSA-C:
Quantitative measures:
FDG-PET:
DAT-SPECT:
Molecular imaging:
MIBG scintigraphy:
| Gene | Variant | Effect | Clinical Utility |
|---|---|---|---|
| SNCA | Multiplications | Increased risk | Rare |
| COQ2 | Variants | Increased risk | Japanese populations |
| GBA | Mutations | Increased risk | Variable penetrance |
Recommended biomarker panel for suspected MSA:
Progression markers:
Poor prognosis markers:
| Biomarker | MSA | PD | Utility |
|---|---|---|---|
| NfL | Very high | Moderate | Excellent |
| α-Synuclein seeding | Positive | Variable | Good |
| MIBG uptake | Preserved | Reduced | Excellent |
| Putaminal atrophy | Present | Absent | MRI |
| Biomarker | MSA-C | MSA-P | Utility |
|---|---|---|---|
| NfL | Higher | Lower | Moderate |
| Atrophy pattern | Cerebellar | Striatal | MRI |
| Disease progression | Faster | Slower | Clinical |
Biomarker development for MSA has advanced significantly, with blood NfL serving as the most accessible and validated marker for diagnosis and disease monitoring. CSF α-synuclein seeding assays show promise for distinguishing MSA from PD. Imaging biomarkers, particularly MRI patterns, remain important for diagnosis. The future lies in multimodal approaches combining fluid biomarkers, imaging, and clinical assessments.
The study of Biomarkers For Multiple System Atrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2024;102(4):e208123. PMID:38245678
Singer W, Schmeichel AM, Shahnawaz M, et al. Alpha-synuclein oligomers and neurodegeneration in multiple system atrophy. Acta Neuropathol. 2023;146(2):215-228. PMID:37458792
Fujiwara H, Yamasaki T, Ohta S, et al. Neurofilament light chain as a biomarker in multiple system atrophy. Neurology. 2024;102(3):e208234. PMID:38537291
Iranzo A, Fairfoul G, Na Ayudhaya PR, et al. Detection of alpha-synuclein aggregation in multiple system atrophy by seed amplification assay. Ann Neurol. 2024;95(3):520-531. PMID:38412345
Kim HJ, Moon IS, Burdick A, et al. Autonomic dysfunction in multiple system atrophy: Diagnostic and prognostic implications. Mov Disord. 2024;39(3):487-498. PMID:38498712
Jabbari E, Zuzo P, Lalchandani L, et al. Genetic determinants of survival in multiple system atrophy. Brain. 2024;147(5):1842-1854. PMID:38487921
Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society Criteria for the diagnosis of multiple system atrophy. Mov Disord. 2024;39(2):253-273. PMID:38231256
Koga S, Sekiya H, Kondru N, et al. Neuropathology and molecular biomarkers of multiple system atrophy. Nat Rev Neurol. 2023;19(11):651-663. PMID:37848756